Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: GlobeNewswire
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access, equity and affordability. “As a former CMO of Medicare and now CMO of a leading health insurance company, Kate has had an indelible impact on how government and private sector entities approach value-based care,” said Bobak Azamian, M.D., Ph.D., CEO and Chairman of Tarsus. “Her passion for ensu
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks [Seeking Alpha]Seeking Alpha
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $41.00. They now have a "neutral" rating on the stock.MarketBeat
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $63.00 to $65.00. They now have an "outperform" rating on the stock.MarketBeat
- Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]Yahoo! Finance
- Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business AchievementsGlobeNewswire
TARS
Earnings
- 11/13/24 - Beat
TARS
Sec Filings
- 12/19/24 - Form 8-K
- 11/15/24 - Form 4
- 11/15/24 - Form 3
- TARS's page on the SEC website